<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02049632</url>
  </required_header>
  <id_info>
    <org_study_id>SENOMIC</org_study_id>
    <nct_id>NCT02049632</nct_id>
  </id_info>
  <brief_title>Sentinel Node Biopsy in Breast Cancner: Omission of Axillary Clearance After Micrometastasis</brief_title>
  <acronym>SENOMIC</acronym>
  <official_title>Survival and Axillary Relapse in Breast Cancer Patients With Sentinel Node Micrometastases Who Have Not Undergone Completion Axillary Clearance - a National Cohort Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Karolinska Institutet</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Centrallasarettet Västerås</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Uppsala University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Karolinska Institutet</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Sentinel node (SN) biopsy in breast cancer has been demonstrated to be a reliable method, and
      several follow-up studies have shown that it is safe to refrain from completion axillary
      clearance (axillary lymph node dissection, ALND) in SN-negative patients. SN biopsy alone
      results in significantly less arm discomfort following the operation.

      However, as a surprisingly low frequency of axillary relapse has been observed in patients
      without any axillary intervention (neither SN biopsy nor axillary clearance), or without
      completion ALND after a positive SN biopsy, the importance of ALND is being questioned, even
      for patients with SN metastases. A large, randomized study (ISBCG23-1) was not able to show
      any differences in 5-year disease-free survival between patients with SN micrometastases who
      had undergone ALND and those who had not.

      This Swedish multicenter study will include patients with SN micrometastases. These women
      will not undergo ALND but will be registered in a study cohort. The patients will otherwise
      be treated in accordance with the national guidelines and will be clinically followed every
      year for five years, after 10 years and finally after 15 years. Hypothesis: To refrain from
      axillary clearance in breast cancer patients with sentinel node micrometastases does not
      impair survival.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      From April 2017 onwards, only patients operated by mastectomy or those receiving neoadjuvant
      therapy and having a sentinel node biopsy before its initiation may be recruited into
      SENOMIC. The inclusion target has been met for those patients operated by breast-conserving
      therapy, and from now on, these patients will not be included in SENOMIC anymore. Recruitment
      of the above-mentioned patient selection will continue until 452 patients operated by
      mastectomy have been enrolled.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2013</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease-free survival</measure>
    <time_frame>Five years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Axillary recurrence rate</measure>
    <time_frame>Five years</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Breast cancer-specific survival</measure>
    <time_frame>Five years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Overall survival</measure>
    <time_frame>Five years</time_frame>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">452</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Omission of axillary clearance</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>No axillary lymph node dissection after sentinel node biopsy and sentinel node micrometastases</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Omission of axillary clearance</intervention_name>
    <arm_group_label>Omission of axillary clearance</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with clinically node-negative, invasive breast cancer ≤ 5 cm (T1-T2)

          -  Histopathology results demonstrate SN micrometastases.

          -  Patients who undergo mastectomy (protocol change from April 2017 onwards)

          -  The patient must have given verbal and written consent.

        Exclusion Criteria:

          -  Preoperatively diagnosed lymph node metastases.

          -  Sentinel node metastases &gt; 2 mm.

          -  Metastases beyond the ipsilateral axillary lymph nodes at the time of surgery.

          -  History of previous breast cancer.

          -  Pregnancy.

          -  Bilateral breast cancer where any of the other exclusion criteria applies to either
             side.

          -  Medical contraindication for systemic adjuvant therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jana M de Boniface, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Karolinska Institutet</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jan Frisell, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Karolinska Institutet</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Leif Bergkvist, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Uppsala University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yvette Andersson, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Västmanlands Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jana M de Boniface, Ass.Prof.</last_name>
    <email>jana.de-boniface@ki.se</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jan Frisell, Professor</last_name>
    <phone>+46851770000</phone>
    <email>jan.frisell@ki.se</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Sahlgrenska University Hospital</name>
      <address>
        <city>Gothenburg</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Roger Olofsson, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Helsingborgs Hospital</name>
      <address>
        <city>Helsingborg</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Anna-Karin Falck, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kalmar Hospital</name>
      <address>
        <city>Kalmar</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Marie Sundqvist</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Karlskrona Hospital</name>
      <address>
        <city>Karlskrona</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Monika Sjövall</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kristianstad Hospital</name>
      <address>
        <city>Kristianstad</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Bertil Sjölund</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lidköping Hospital</name>
      <address>
        <city>Lidköping</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Per Nyman</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Linköping University Hospital</name>
      <address>
        <city>Linköping</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Christina Hedin</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lund and Malmö University Hospital</name>
      <address>
        <city>Lund</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Lisa Rydén, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Skövde Hospital</name>
      <address>
        <city>Skövde</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Anja Jungquist</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Karolinska University Hospital</name>
      <address>
        <city>Stockholm</city>
        <zip>17176</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jan M Frisell, Prof</last_name>
      <phone>+4685770000</phone>
      <email>jan.frisell@ki.se</email>
    </contact>
    <investigator>
      <last_name>Jan Frisell, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Capio St Görans Hospital</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Sophie Norenstedt, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Danderyds Hospital AB</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Kristina Dahlberg, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Southern General Hospital</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Fuat Celebioglu, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sundsvall Hospital</name>
      <address>
        <city>Sundsvall</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Lotta Wadsten</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Uddevalla Hospital</name>
      <address>
        <city>Uddevalla</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Carin Wångblad</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Umeå University Hospital</name>
      <address>
        <city>Umeå</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Malin Sund, Professor</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Akademiska Universitetssjukhuset</name>
      <address>
        <city>Uppsala</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Fredrik Wärnberg, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Varberg Hospital</name>
      <address>
        <city>Varberg</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Michael Wallberg</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Västervik Hospital</name>
      <address>
        <city>Västervik</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Peter Gustafsson</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Västmanlands Hospital</name>
      <address>
        <city>Västerås</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yvette Andersson, MD, PhD</last_name>
      <email>yvette.andersson@ltv.se</email>
    </contact>
    <investigator>
      <last_name>Yvette Andersson, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Växjö Hospital</name>
      <address>
        <city>Växjö</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Lena Myrskog</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Örebro University Hospital</name>
      <address>
        <city>Örebro</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Daniel Tegnelius</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 24, 2014</study_first_submitted>
  <study_first_submitted_qc>January 28, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 30, 2014</study_first_posted>
  <last_update_submitted>August 30, 2017</last_update_submitted>
  <last_update_submitted_qc>August 30, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 31, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Karolinska University Hospital</investigator_affiliation>
    <investigator_full_name>Jana de Boniface</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>Breast cancer</keyword>
  <keyword>Sentinel Node Biopsy</keyword>
  <keyword>Micrometastasis</keyword>
  <keyword>Axillary lymph node dissection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Neoplasm Micrometastasis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

